Hydroxyurea for Children with Sickle Cell Disease  

Oleh:

Heeney, Matthew M ; Ware, Russell E.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Pediatric Clinics of North America vol. 55 no. 02 (Apr. 2008), page 483.
Topik: Pediatric Hematology

Ketersediaan

Perpustakaan FK Nomor Panggil: P13.K.2008.02 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Hydroxyurea therapy offers promise for ameliorating the clinical course of children with sickle cell disease (SCD). Hydroxyurea is a prototypic therapeutic option; it can be administered with minimal sede effects, has a relatively wide therapeutic window, and has mechanisms of action that address pathophysiologic pathways of sickling, vaso-occlusion, hemolysis, and organ damage. There are limeted data regarding hydroxyurea's ability to prevent or diminish organ dysfunction, and the long-term risks of hydroxyurea therapy remain incompletely defined. Although clinical trials are underway to address long-term issues, hydroxyurea remains an effective but underutilized therapy for SCD.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali